Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 100 movers: Experian rallies; AZN hit by downgrade
(Sharecast News) - London's FTSE 100 was down 0.4% at 7,561.57 in afternoon trade on Tuesday. Experian rallied as it narrowed its full-year targets to the upper end of guidance after a strong third quarter with revenue growth accelerating from the first half.
Ocado gained after the online grocer forecast a return to positive earnings for 2022/23 year as fourth-quarter revenues rose by almost 11%.
Housebuilder Persimmon was boosted by an upgrade to 'buy' from hold' at Jefferies, which said it sees scope for a meaningful change in sentiment towards the group, given its position to leverage into an improving market.
Rightmove took a hit after JPMorgan Cazenove downgraded the shares to 'underweight' from 'neutral' and cut the price target to 493p from 585p as it pointed to higher R&D and opex spend.
AstraZeneca was in the red after UBS downgraded the shares to 'sell' from 'buy'.
"Our key concern is the exposure of the company to US Medicare Part D reform, which slows our sales growth assumptions from 2025," it said. "We see AstraZeneca's oral oncology portfolio as particularly exposed to the requirement for pharma to fund 20% of catastrophic cover from 2025, up from around 2%.
"This forced effective price cut, coupled with likely increased PMB formulary pressures, means we are around 5% below consensus core earnings before interest and tax for 2025/26.
"On the positive side, our view of probability-adjusted mid-stage pipeline means we are modestly above consensus by 2028/29."
FTSE 100 - Risers
Experian (EXPN) 3,193.00p 2.14% Ocado Group (OCDO) 631.20p 1.97% Hikma Pharmaceuticals (HIK) 1,964.50p 1.63% Burberry Group (BRBY) 1,231.50p 1.61% Rio Tinto (RIO) 5,500.00p 1.10% Compass Group (CPG) 2,212.00p 1.00% Persimmon (PSN) 1,464.00p 0.93% BP (BP.) 457.15p 0.92% United Utilities Group (UU.) 1,058.00p 0.67% Haleon (HLN) 335.90p 0.54%
FTSE 100 - Fallers
Rightmove (RMV) 537.80p -4.78% JD Sports Fashion (JD.) 109.05p -3.75% AstraZeneca (AZN) 10,576.00p -2.54% Fresnillo (FRES) 515.60p -2.20% BT Group (BT.A) 113.95p -2.02% Legal & General Group (LGEN) 247.40p -2.02% Airtel Africa (AAF) 128.20p -1.76% International Consolidated Airlines Group SA (CDI) (IAG) 142.95p -1.75% Scottish Mortgage Inv Trust (SMT) 760.80p -1.65% Frasers Group (FRAS) 809.00p -1.58%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
